VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q126289807  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241121000005.0
008     241121nneanz||abbn n and d
035 ‎‡a  (WKP)Q126289807‏
035 ‎‡a  (OCoLC)Q126289807‏
043 ‎‡c  NZ‏
046 ‎‡f  19400000‏
100 0 ‎‡a  John P. V. Collins‏ ‎‡c  New Zealand breast surgeon‏ ‎‡9  en‏
375 ‎‡a  1‏ ‎‡2  iso5218‏
400 0 ‎‡a  John Collins‏ ‎‡9  eo‏ ‎‡9  scn‏ ‎‡9  co‏ ‎‡9  io‏ ‎‡9  af‏ ‎‡9  vmf‏ ‎‡9  vi‏ ‎‡9  ca‏ ‎‡9  it‏ ‎‡9  an‏ ‎‡9  eu‏ ‎‡9  cy‏ ‎‡9  gd‏ ‎‡9  pt-br‏ ‎‡9  ga‏ ‎‡9  zu‏ ‎‡9  cs‏ ‎‡9  et‏ ‎‡9  gl‏ ‎‡9  ie‏ ‎‡9  id‏ ‎‡9  es‏ ‎‡9  en-gb‏ ‎‡9  lb‏ ‎‡9  wa‏ ‎‡9  nn‏ ‎‡9  min‏ ‎‡9  nb‏ ‎‡9  pms‏ ‎‡9  tr‏ ‎‡9  nap‏ ‎‡9  lij‏ ‎‡9  li‏ ‎‡9  wo‏ ‎‡9  lt‏ ‎‡9  frp‏ ‎‡9  nds-nl‏ ‎‡9  br‏ ‎‡9  rm‏ ‎‡9  ro‏ ‎‡9  ia‏ ‎‡9  sr-el‏ ‎‡9  pcd‏ ‎‡9  vec‏ ‎‡9  kab‏ ‎‡9  sco‏ ‎‡9  nrm‏ ‎‡9  ast‏ ‎‡9  hr‏ ‎‡9  bm‏ ‎‡9  de‏ ‎‡9  hu‏ ‎‡9  rgn‏ ‎‡9  da‏ ‎‡9  fr‏ ‎‡9  prg‏ ‎‡9  mi‏ ‎‡9  fi‏ ‎‡9  vls‏ ‎‡9  vo‏ ‎‡9  kg‏ ‎‡9  en-ca‏ ‎‡9  jam‏ ‎‡9  mg‏ ‎‡9  bar‏ ‎‡9  pt‏ ‎‡9  gsw‏ ‎‡9  sc‏ ‎‡9  fur‏ ‎‡9  sw‏ ‎‡9  sv‏ ‎‡9  de-ch‏ ‎‡9  frc‏ ‎‡9  sk‏ ‎‡9  pap‏ ‎‡9  oc‏ ‎‡9  ms‏ ‎‡9  de-at‏ ‎‡9  nds‏ ‎‡9  nl‏ ‎‡9  pl‏
670 ‎‡a  Author's Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII‏
670 ‎‡a  Author's Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV.‏
670 ‎‡a  Author's Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results‏
670 ‎‡a  Author's Delay in seeking medical care for self-detected breast symptoms in New Zealand women‏
670 ‎‡a  Author's Hormone replacement therapy and breast cancer, revisited‏
670 ‎‡a  Author's Hormones and breast cancer: should practice be changed?‏
670 ‎‡a  Author's Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.‏
670 ‎‡a  Author's Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93‏
670 ‎‡a  Author's Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker?‏
670 ‎‡a  Author's Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials‏
670 ‎‡a  Author's Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century‏
670 ‎‡a  Author's Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Bre‏
670 ‎‡a  Author's Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience.‏
670 ‎‡a  Author's The relationship of symptoms and psychological factors to delay in seeking medical care for breast symptoms‏
919 ‎‡a  hormonesandbreastcancershouldpracticebechanged‏ ‎‡A  Hormones and breast cancer: should practice be changed?‏ ‎‡9  1‏
919 ‎‡a  adjuvantchemotherapyfollowedbygoserelincomparedwitheithermodalityalonetheimpactonamenorrheahotflashesandqualityoflifeinpremenopausalpatientstheinternationalbreastcancerstudygrouptrial8‏ ‎‡A  Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII‏ ‎‡9  1‏
919 ‎‡a  decreasedimmunoreactivityforp27proteininpatientswithearlystagebreastcarcinomaiscorrelatedwithher2neuoverexpressionandwithbenefitfrom1courseofperioperativechemotherapyinpatientswithnegativelymphnodestatusresults‏ ‎‡A  Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results‏ ‎‡9  1‏
919 ‎‡a  delayinseekingmedicalcareforselfdetectedbreastsymptomsinnewzealandwomen‏ ‎‡A  Delay in seeking medical care for self-detected breast symptoms in New Zealand women‏ ‎‡9  1‏
919 ‎‡a  hormonereplacementtherapyandbreastcancerrevisited‏ ‎‡A  Hormone replacement therapy and breast cancer, revisited‏ ‎‡9  1‏
919 ‎‡a  isadjuvantchemotherapyofbenefitforpostmenopausalwomenwhoreceiveendocrinetreatmentforhighlyendocrineresponsivenodepositivebreastcancerinternationalbreastcancerstudygrouptrials7and1293‏ ‎‡A  Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.‏ ‎‡9  1‏
919 ‎‡a  ischemotherapynecessaryforpremenopausalwomenwithlowerrisknodepositiveendocrineresponsivebreastcancer10yearupdateofinternationalbreastcancerstudygrouptrial1193‏ ‎‡A  Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93‏ ‎‡9  1‏
919 ‎‡a  ki67expressioninbreastcarcinomaitsassociationwithgradingsystemsclinicalparametersandotherprognosticfactorsasurrogatemarker‏ ‎‡A  Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker?‏ ‎‡9  1‏
919 ‎‡a  oculartoxicityduringadjuvantchemoendocrinetherapyforearlybreastcancerresultsfrominternationalbreastcancerstudygrouptrials‏ ‎‡A  Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials‏ ‎‡9  1‏
919 ‎‡a  patternsofrecurrenceofearlybreastcanceraccordingtoestrogenreceptorstatusatherapeutictargetforaquarterofacentury‏ ‎‡A  Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century‏ ‎‡9  1‏
919 ‎‡a  prognosticvalueofextracapsulartumorspreadforlocoregionalcontrolinpremenopausalpatientswithnodepositivebreastcancertreatedwithclassicalcyclophosphamidemethotrexateandfluorouracillongtermobservationsfrominternationalbre‏ ‎‡A  Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Bre‏ ‎‡9  1‏
919 ‎‡a  siteofprimarytumorhasaprognosticroleinoperablebreastcancertheinternationalbreastcancerstudygroupexperience‏ ‎‡A  Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience.‏ ‎‡9  1‏
919 ‎‡a  relationshipofsymptomsandpsychologicalfactorstodelayinseekingmedicalcareforbreastsymptoms‏ ‎‡A  The relationship of symptoms and psychological factors to delay in seeking medical care for breast symptoms‏ ‎‡9  1‏
919 ‎‡a  adjuvantendocrinetherapycomparedwithnosystemictherapyforelderlywomenwithearlybreastcancer21yearresultsofinternationalbreastcancerstudygrouptrial4‏ ‎‡A  Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV.‏ ‎‡9  1‏
946 ‎‡a  b‏ ‎‡9  1‏
947 ‎‡a  NZ‏ ‎‡9  1‏
996 ‎‡2  LC|no2006072871‏
996 ‎‡2  LC|n 2008067873‏
996 ‎‡2  ISNI|0000000033600265‏
996 ‎‡2  ISNI|0000000042349957‏
996 ‎‡2  LC|nr 91023585‏
996 ‎‡2  PLWABN|9814147056505606‏
996 ‎‡2  NII|DA05716167‏
996 ‎‡2  ISNI|0000000038741032‏
996 ‎‡2  LC|n 2017053051‏
996 ‎‡2  NTA|068680201‏
996 ‎‡2  SUDOC|035217073‏
996 ‎‡2  DBC|87097919200914‏
996 ‎‡2  DE633|pe30012149‏
996 ‎‡2  BIBSYS|90231598‏
996 ‎‡2  NII|DA05043259‏
996 ‎‡2  LC|n 82127339‏
996 ‎‡2  ISNI|0000000113620194‏
996 ‎‡2  SUDOC|060341505‏
996 ‎‡2  LC|n 81065012‏
996 ‎‡2  PLWABN|9810660090805606‏
996 ‎‡2  LC|nr 92006110‏
996 ‎‡2  LC|n 90677130‏
996 ‎‡2  BIBSYS|90338368‏
996 ‎‡2  BNF|16214480‏
996 ‎‡2  NTA|330353454‏
996 ‎‡2  DNB|1246803771‏
996 ‎‡2  N6I|vtls000064826‏
996 ‎‡2  DNB|118087142‏
996 ‎‡2  ISNI|0000000497220172‏
996 ‎‡2  NII|DA07926262‏
996 ‎‡2  NTA|41974245X‏
996 ‎‡2  DNB|1147173257‏
996 ‎‡2  J9U|987007448791505171‏
996 ‎‡2  N6I|vtls000037485‏
996 ‎‡2  NUKAT|n 2016177214‏
996 ‎‡2  SUDOC|104147989‏
996 ‎‡2  LC|n 2014053422‏
996 ‎‡2  LC|no 99052869‏
996 ‎‡2  NII|DA05798525‏
996 ‎‡2  N6I|vtls000061998‏
996 ‎‡2  ISNI|0000000460790446‏
996 ‎‡2  BNF|12030625‏
996 ‎‡2  LIH|LNB:BP_o__t_;=CF‏
996 ‎‡2  NII|DA11315590‏
996 ‎‡2  LC|n 79130412‏
996 ‎‡2  NII|DA04735417‏
996 ‎‡2  LC|no2016079699‏
996 ‎‡2  CAOONL|ncf10733985‏
996 ‎‡2  NLA|000035029842‏
996 ‎‡2  RERO|A021712462‏
996 ‎‡2  NII|DA19414370‏
996 ‎‡2  PTBNP|939644‏
996 ‎‡2  SUDOC|191917230‏
996 ‎‡2  NII|DA04712182‏
996 ‎‡2  NII|DA0723230X‏
996 ‎‡2  ISNI|0000000027232865‏
996 ‎‡2  NTA|075268248‏
996 ‎‡2  LC|no2015168982‏
996 ‎‡2  NSK|000316153‏
996 ‎‡2  LC|no2019041670‏
996 ‎‡2  LC|no 96035920‏
996 ‎‡2  J9U|987007425549405171‏
996 ‎‡2  CAOONL|ncf12126962‏
996 ‎‡2  LC|n 2016015022‏
996 ‎‡2  SUDOC|155413457‏
996 ‎‡2  SUDOC|148411223‏
996 ‎‡2  DNB|1157886515‏
996 ‎‡2  PTBNP|1850608‏
996 ‎‡2  LC|n 2014181793‏
996 ‎‡2  PLWABN|9810702865905606‏
996 ‎‡2  CAOONL|ncf11344518‏
996 ‎‡2  ISNI|0000000041333216‏
996 ‎‡2  LC|n 98109847‏
996 ‎‡2  BNF|12985771‏
996 ‎‡2  ISNI|0000000459551421‏
996 ‎‡2  NUKAT|n 2019033351‏
996 ‎‡2  CAOONL|ncf10014556‏
996 ‎‡2  LC|n 89134956‏
996 ‎‡2  ERRR|12605669‏
996 ‎‡2  LC|n 86851466‏
996 ‎‡2  DNB|1191197344‏
996 ‎‡2  LC|n 90641672‏
996 ‎‡2  SUDOC|060258195‏
996 ‎‡2  N6I|vtls000052983‏
996 ‎‡2  DNB|1048207803‏
996 ‎‡2  DNB|1011297442‏
996 ‎‡2  LC|no2019010788‏
996 ‎‡2  DNB|188356363‏
996 ‎‡2  LC|n 83205277‏
996 ‎‡2  NII|DA07940547‏
996 ‎‡2  LIH|LNB:CGDW;=BB‏
996 ‎‡2  ISNI|000000005082405X‏
996 ‎‡2  N6I|vtls000032437‏
996 ‎‡2  ISNI|0000000111544669‏
996 ‎‡2  LC|nb2002066411‏
996 ‎‡2  PLWABN|9810543511405606‏
996 ‎‡2  RERO|A003116981‏
996 ‎‡2  DNB|1179268253‏
996 ‎‡2  NTA|321817745‏
996 ‎‡2  LC|n 85290455‏
996 ‎‡2  RERO|A003116979‏
996 ‎‡2  N6I|vtls000083858‏
996 ‎‡2  RERO|A003116974‏
996 ‎‡2  CAOONL|ncf10114118‏
996 ‎‡2  N6I|vtls000110717‏
996 ‎‡2  LC|no2021119044‏
996 ‎‡2  NII|DA02107559‏
996 ‎‡2  LC|no 97053045‏
996 ‎‡2  LC|no 00002041‏
996 ‎‡2  CAOONL|ncf10297781‏
996 ‎‡2  ISNI|0000000118794505‏
996 ‎‡2  SUDOC|184934095‏
996 ‎‡2  BLBNB|000396577‏
996 ‎‡2  NTA|067813097‏
996 ‎‡2  SUDOC|261695444‏
996 ‎‡2  DNB|1122867573‏
996 ‎‡2  J9U|987007362166705171‏
996 ‎‡2  BIBSYS|3103209‏
996 ‎‡2  LIH|LNB:DT_y_V;=B9‏
996 ‎‡2  ISNI|0000000067774984‏
996 ‎‡2  NTA|070925577‏
996 ‎‡2  DNB|1312981636‏
996 ‎‡2  ISNI|0000000023695272‏
996 ‎‡2  CAOONL|ncf11490223‏
996 ‎‡2  SUDOC|255821441‏
996 ‎‡2  LC|n 82215388‏
996 ‎‡2  LC|nb 98091230‏
996 ‎‡2  BIBSYS|90859153‏
996 ‎‡2  LC|no2020116066‏
996 ‎‡2  BIBSYS|11043581‏
996 ‎‡2  ISNI|0000000459841808‏
996 ‎‡2  ISNI|0000000078485141‏
996 ‎‡2  SUDOC|084592176‏
996 ‎‡2  ISNI|0000000363454109‏
996 ‎‡2  DNB|1180329481‏
996 ‎‡2  ISNI|000000040925690X‏
996 ‎‡2  J9U|987007452864505171‏
996 ‎‡2  NII|DA06842280‏
996 ‎‡2  NTA|338806105‏
996 ‎‡2  N6I|vtls000356819‏
996 ‎‡2  ISNI|0000000391430964‏
996 ‎‡2  LC|n 82033924‏
996 ‎‡2  UAE|Mill_a10000596‏
996 ‎‡2  LC|no2019040010‏
996 ‎‡2  ISNI|0000000445020072‏
996 ‎‡2  LC|n 82136059‏
996 ‎‡2  J9U|987012500863005171‏
996 ‎‡2  BNF|12373900‏
996 ‎‡2  SUDOC|199610924‏
996 ‎‡2  LC|nr2002037297‏
996 ‎‡2  LC|n 81088528‏
996 ‎‡2  N6I|vtls000115259‏
996 ‎‡2  LC|no2017087805‏
996 ‎‡2  RERO|A003116982‏
996 ‎‡2  RERO|A003116985‏
996 ‎‡2  RERO|A003116984‏
996 ‎‡2  RERO|A003116987‏
996 ‎‡2  LC|n 92026277‏
996 ‎‡2  LC|n 2016035691‏
996 ‎‡2  SUDOC|220951241‏
996 ‎‡2  LC|n 79136644‏
996 ‎‡2  DNB|174079443‏
996 ‎‡2  J9U|987007376419105171‏
996 ‎‡2  DNB|1103505343‏
996 ‎‡2  SUDOC|081353847‏
996 ‎‡2  NUKAT|n 2021200946‏
996 ‎‡2  RERO|A012342057‏
996 ‎‡2  DNB|1057415073‏
996 ‎‡2  LC|no2021030833‏
996 ‎‡2  NTA|074493485‏
996 ‎‡2  LC|nr 89015836‏
996 ‎‡2  BAV|495_109093‏
996 ‎‡2  SUDOC|032916027‏
996 ‎‡2  BIBSYS|3077669‏
996 ‎‡2  LC|nb2001037788‏
996 ‎‡2  NII|DA0040648X‏
996 ‎‡2  LC|no 91027390‏
996 ‎‡2  NUKAT|n 2012179680‏
996 ‎‡2  BIBSYS|90233353‏
996 ‎‡2  ISNI|0000000116653493‏
996 ‎‡2  N6I|vtls000055023‏
996 ‎‡2  ISNI|000000003335560X‏
996 ‎‡2  ISNI|0000000021912632‏
996 ‎‡2  ISNI|0000000368883092‏
996 ‎‡2  N6I|vtls000854851‏
996 ‎‡2  PTBNP|1602644‏
996 ‎‡2  BIBSYS|1025709‏
996 ‎‡2  LC|no2002060985‏
996 ‎‡2  NTA|229399967‏
996 ‎‡2  J9U|987007334449005171‏
996 ‎‡2  BIBSYS|90618033‏
996 ‎‡2  NII|DA17639653‏
996 ‎‡2  NII|DA03553516‏
996 ‎‡2  BIBSYS|90184943‏
996 ‎‡2  LC|n 90629026‏
996 ‎‡2  RERO|A016565474‏
996 ‎‡2  LC|n 84161684‏
996 ‎‡2  ISNI|0000000383349226‏
996 ‎‡2  ISNI|0000000070640725‏
996 ‎‡2  BIBSYS|90361596‏
996 ‎‡2  NUKAT|n 2012241173‏
996 ‎‡2  LC|n 82127250‏
996 ‎‡2  PLWABN|9810562020705606‏
996 ‎‡2  LC|no2002064802‏
996 ‎‡2  LC|no2005092571‏
996 ‎‡2  ISNI|0000000116330766‏
996 ‎‡2  BNF|14487639‏
996 ‎‡2  LC|nb2011001866‏
996 ‎‡2  ISNI|0000000391071850‏
996 ‎‡2  DE633|pe40001646‏
996 ‎‡2  BNF|16537527‏
996 ‎‡2  DNB|1059142899‏
996 ‎‡2  NTA|160331501‏
996 ‎‡2  LC|n 80100215‏
996 ‎‡2  SUDOC|076746941‏
996 ‎‡2  LC|no2016096928‏
996 ‎‡2  ISNI|0000000506342842‏
996 ‎‡2  ISNI|0000000436795757‏
996 ‎‡2  BNF|12385283‏
996 ‎‡2  SUDOC|278657567‏
996 ‎‡2  RERO|A011244835‏
996 ‎‡2  LNB|LNC10-000057016‏
996 ‎‡2  DNB|133770834‏
996 ‎‡2  LC|n 86818079‏
996 ‎‡2  ISNI|0000000022895977‏
996 ‎‡2  LC|n 82128356‏
996 ‎‡2  BIBSYS|7057924‏
996 ‎‡2  CAOONL|ncf10152745‏
996 ‎‡2  NTA|069650829‏
996 ‎‡2  J9U|987007401409605171‏
996 ‎‡2  B2Q|0000131042‏
996 ‎‡2  J9U|987007313047005171‏
996 ‎‡2  RERO|A003116959‏
996 ‎‡2  DNB|123520282‏
996 ‎‡2  ISNI|0000000500097727‏
996 ‎‡2  NII|DA09576842‏
996 ‎‡2  LC|n 81064559‏
996 ‎‡2  ISNI|000000007382452X‏
996 ‎‡2  J9U|987007326026505171‏
996 ‎‡2  PLWABN|9810573265105606‏
996 ‎‡2  LC|n 82160079‏
996 ‎‡2  DNB|1349297542‏
996 ‎‡2  NUKAT|n 2010135675‏
996 ‎‡2  ISNI|0000000031379536‏
996 ‎‡2  J9U|987007455391005171‏
996 ‎‡2  BIBSYS|90859148‏
996 ‎‡2  ICCU|CFIV181045‏
996 ‎‡2  DNB|1029843996‏
996 ‎‡2  LC|n 82256982‏
996 ‎‡2  BNF|15071705‏
997 ‎‡a  1940 0 lived 0000 0‏ ‎‡9  1‏